Roche pulls Tecentriq breast cancer nod after post-approval trial flop

Just two years ago, Roche’s Tecentriq was heralded as the first PD-1/L1 treatment to win an approval in triple-negative breast cancer. However, the approval was conditional on a postmarketing study on the Tencentriq and Celgene’s Abraxane combo which later failed.

Now Roche is pulling the plug.